Abstract

Introduction: Durable antitumor activity has been observed with cemiplimab and pembrolizumab in advanced metastatic cSCC. The randomized, double-blind, phase 3 KEYNOTE-630 study (NCT03833167) will evaluate adjuvant pembrolizumab in resectable, high-risk, LA cSCC.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call